GlassScriptPhysician profile
Kai A Bickenbach
NPI 1295976389
$7,287.24
in general payments reported to CMS, 2019-2025
34 companies · $668 in 2025
The $668 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $304 · 2021: $919 · 2022: $849 · 2023: $943 · 2024: $3,206 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,440 · Food and Beverage: $2,308 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,440.00 |
| Food and Beverage | $2,308.17 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,578.74 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,326.49 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $471.11 | 2019-2025 | |
| Daiichi Sankyo INC. | $458.63 | 2022-2025 | Enhertu, Vanflyta |
| Genzyme Corporation | $242.66 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $240.31 | 2019-2022 | |
| Mirati Therapeutics, INC. | $233.83 | 2023-2024 | Krazati |
| Seagen INC. | $199.73 | 2022-2023 | Tukysa |
| Eisai INC. | $153.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $132.50 | 2019-2025 | Imfinzi, Calquence |
| Boston Scientific Corporation | $118.80 | 2021 | |
| Acera Surgical, INC. | $108.69 | 2023-2025 | Restrata Wound Matrix |
| Incyte Corporation | $105.26 | 2020-2025 | Monjuvi, Zynyz |
| Amgen INC. | $94.42 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $94.27 | 2022-2023 | Xpovio |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $93.51 | 2023-2025 | Odomzo, Yonsa |
| Abbvie INC. | $71.18 | 2019-2022 | |
| Astellas Pharma US INC | $67.20 | 2020-2023 | Xospata |
| Janssen Biotech, INC. | $64.71 | 2020-2024 | Talvey, Tecvayli, Darzalex |
| Kerecis Limited | $59.35 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Genentech USA, INC. | $55.38 | 2019-2021 | |
| Pfizer INC. | $47.04 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $46.22 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $42.22 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $29.54 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.03 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $19.00 | 2025 | Sancuso |
| Stemline Therapeutics INC. | $17.35 | 2024 | Orserdu |
| Glaxosmithkline, LLC. | $16.94 | 2022 | |
| Galvanize Therapeutics, INC | $15.76 | 2024 | Aliya System |
| W. L. Gore & Associates, INC. | $14.87 | 2019 | |
| Tesaro, INC. | $14.51 | 2019 | |
| Exelixis INC. | $13.92 | 2021 | |
| Celgene Corporation | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Bickenbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.